CYP2D6*11 and challenges in clinical genotyping of the highly polymorphic CYP2D6 gene

Pharmacogenomics

Volumn 13, Issue 8, 2012, Pages 951-954

  Skierka, Jennifer M ^a   Walker, Denise L ^b   Peterson, Sandra E ^a   O'Kane, Dennis J ^a   Black, John Logan ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

CYP2D6; nomenclature; pharmacogenomic

Indexed keywords

ADENINE; CYTOSINE; GUANINE; PSYCHOTROPIC AGENT; TAMOXIFEN; THYMINE; CYTOCHROME P450 2D6;

ACCURACY; ALLELE; ARTICLE; CLINICAL LABORATORY; COPY NUMBER VARIATION; CYP2D6 GENE; DIAGNOSTIC TEST; DNA POLYMORPHISM; DNA SEQUENCE; DRUG RESPONSE; EXON; GENE; GENE CONVERSION; GENE DELETION; GENE DUPLICATION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HYBRID; IN VITRO STUDY; INTRON; MEDICAL DECISION MAKING; NOMENCLATURE; PHARMACOGENOMICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTION; PROMOTER REGION; CLASSIFICATION; GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; CYTOCHROME P-450 CYP2D6; GENE DELETION; GENE DUPLICATION; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84862004280     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.56     Document Type: Article

References (12)

1. Purich D, Allison R. The Enzyme Reference: a Comprehensive Guide to Enzyme Nomenclature, Reactions, and Methods. Academic Press, Elsevier Science, CA, USA (2002).
2. Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226, 327-338 (1999).
3. Marez D, Legrand M, Sabbagh N et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7, 193-202 (1997).
4. Marez D, Sabbagh N, Legrand M, Lo-Guidice J, Boone P, Broly F. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics 5(5), 305-311 (1995).
5. Kramer W, Walker D, O'Kane D et al. CYP2D6: novel genomic structures and alleles. Pharmacogenet. Genomics 19, 813-822 (2009). Describes novel arrangements of the CYP2D locus and novel alleles.
6. Black J, Walker D, O'Kane D, Harmandayan M. Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction. Drug Metabol. Disposition 40, 111-119 (2012). Describes novel arrangements of the CYP2D locus and novel hybrid genes as well as frequency of CYP2D6 hybrid genes in clinical samples.
7. Zanger U, Fischer J, Raimundo S et al. Comprehensive ana lysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11, 573-585 (2001).
8. Lovlie R, Daly AK, Matre GE, Molven A, Steen VM. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 11, 45-55 (2001).
9. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger U. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10, 577-581 (2000).
10. CYP2D6 Allele Nomenclature. www.cypalleles.ki.se/cyp2d6.htm (Accessed 7 May 2012)
11. US FDA Guidance for Industry: Pharmacogenomic Data Submissions. www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126957.pdf? utm-campaign=Google2&utm-source=fdaSearch&utm-medium= website&utm-term=pharmacogenomicAND2002&utm-content=3
12. NCBI website. www.ncbi.nlm.nih.gov